On November 6th, 2025, the Trump Administration announced it had reached a deal with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to lower pricing on their popular weight-loss drugs Zepbound (tirzepatide) and Wegovy (semaglutide). The deal also includes expanded coverage of the medications by Medicare and fast-track approval of each company's oral GLP drugs, which are currently being submitted to the FDA for review. Highlights of the agreement include the following:

• Lilly and Novo Nordisk will sell Zepbound and Wegovy directly to consumers at an average price of $350 per month, with a commitment to reduce the average to approximately $250 per month over the next two years. Lilly stated that the starting dose of Zepbound (2.5 mg) will cost $299 per month, and all other doses will cost $449 per month. Current pricing is $349 for the 2.5 mg dose and $499 for all other doses. Novo Nordisk has not said what Wegovy pricing will be.
• Each company's oral GLP therapy (Orforglipron from Lilly and Semaglutide from Novo Nordisk) will receive vouchers for accelerated FDA approval, which can reduce the process to several months, as opposed to a year. In exchange, the companies will offer the starting doses of the drugs directly to consumers for $149 a month. Lilly said that orforglipron prices will be capped at $399 per month for the higher doses. Novo Nordisk has not provided specifics on oral semaglutide pricing.
• Medicare patients with a BMI of 35 or greater will be eligible to receive the drugs for $50 a month. Medicaid coverage will be determined by the individual states. The manufacturers will sell the drugs to the government programs for $245 a month.

This is good news for patient access to these life-changing, weight-loss therapies. When these drugs were first introduced four years ago, prices exceeded $1000 a month. They are now available for less than half that, and competition should continue to drive prices lower.

• Reuters news release about the agreement